Bortezomib is a proteasome inhibitor used in the treatment of multiple myeloma and mantle cell lymphoma. Its impurity profile includes structurally related analogs, stereoisomeric variants, residual solvents, and degradation products formed under stress conditions such as hydrolysis and oxidation. Degradation pathways typically involve hydrolytic cleavage of peptide bonds, oxidation of the boronic acid group, and rearrangements of the benzodioxaborole ring system. These impurities may affect the drug’s potency, stability, and safety. All impurities are structurally characterized and qualified in accordance with ICH guidelines for toxicological assessment and analytical validation.
Pharmacopeial and non-pharmacopeial Bortezomib impurity compounds are available in compliance with European Pharmacopoeia (EP) specifications. These standards support analytical method development, impurity profiling, and long-term stability studies. EP traceable materials are supplied with validated analytical data, including purity, structural confirmation, and spectral characterization.
Structurally related compounds and synthetic analogs associated with Bortezomib are included for use in impurity identification, toxicological qualification, and regulatory submission. These related substances are used in forced degradation studies, genotoxicity assessments, and impurity threshold evaluations. They are essential for understanding the impurity profile and ensuring compliance with regulatory limits.
Bortezomib impurity reference standards are provided with validated analytical data, including purity, NMR, MS, and full Certificates of Analysis. These standards are used in pharmaceutical research, method validation, and GMP-compliant quality control. EP/USP traceable entries are available upon request and are routinely re-tested to ensure consistency and reliability.
Register to add the product to RFQ list
Already have an account? Log in here
Don’t have an account? Register here
